Skip to main content

Table 2 24 month-change in the PRINTO Core Set Measures in Reference Group 1 (N = 30)

From: The PRINTO evidence-based proposal for glucocorticoids tapering/discontinuation in new onset juvenile dermatomyositis patients

 

0 months

0–2 months Absolute change (% change)

2–4 months Absolute

change (% change)

4–6 months Absolute

change (% change)

6–24 months Absolute change (% change)

MD evaluation (0–10 ↑)

7

-3

(− 66.7%)

−1

(− 68.3%)

0

(0%)

0

(0%)

DAS (0–20 ↑)

13

−7

(− 50%)

−2

(− 40%)

−1

(− 33.3%)

−1

(− 6.5%)

CMAS (0–52 ↓)

16.5

+ 16

(+ 93.8%)

+ 4

(+ 15.8%)

+ 1

(+ 2.0%)

+ 1

(+ 3.4%)

MMT (0–80 ↓)

40

+ 20

(+ 53.8%)

+ 6

(+ 8.1%)

+ 1.5(+ 2.1%)

+ 1

(+ 1.3%)

Parent global (0–10 ↑)

6

−4

(− 76.4%)

0

(0%)

0

(0%)

0

(0%)

CHAQ (0–3 ↑)

1.8

−1.2

(−82.5%)

−0.1

(− 28.6%)

0

(0%)

0

(0%)

PhS (40–60 ↓)

19.8

+ 14.2 (+ 53.8%)

+ 8.4 (+ 21.1%)

+3.2 (+ 7.3%)

+ 1.9 (+ 4.3)

  1. Group 1: clinical remission yes- treatment failure no- prednisone off. MD-global: physician’s global assessment of the patient’s overall disease activity on a 0–10-cm visual analogue scale (VAS); Parent global: parents’ global assessment of the child’s overall patient’s well-being on a 10-cm VAS; DAS Disease Activity Score, CMAS Childhood Myositis Assessment Scale, MMT manual muscle testing, CHAQ cross-culturally adapted and validated version of the Childhood Health Assessment Questionnaire; ↑ indicates that higher values correspond toa worse outcome; ↓indicates that lower values correspond to a worse outcome